Prevalence of renal dysfunction according to the type of atrial fibrillation and anticoagulation treatment in patients who attended primary care in Spain

Future Cardiology

Volumn 10, Issue 2, 2014, Pages 215-220

  Barrios, Vivencio ^a   Escobar, Carlos ^b   Calderón, Alberto ^c   Zamorano, Jose L ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Primary Care Center Rosa de Luxemburgo   (Spain)

Author keywords

Anticoagulation; atrial fibrillation; renal disease; vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIET; ELECTROCARDIOGRAM; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MODERATE RENAL IMPAIRMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SPAIN; VASCULAR DISEASE; ATRIAL FIBRILLATION; CLASSIFICATION; EPIDEMIOLOGY; PRIMARY HEALTH CARE; RENAL INSUFFICIENCY, CHRONIC;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PREVALENCE; PRIMARY HEALTH CARE; RENAL INSUFFICIENCY, CHRONIC; SPAIN;

EID: 84899518176     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.14.2     Document Type: Article

References (23)

1. Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127(5), 569-574 (2013).
2. Roldán V, Marín F, Fernández H et al. Renal impairment in a real-life cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am. J. Cardiol. 111(8), 1159-1164 (2013).
3. Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med. 367(7), 625-635 (2012).
4. Salim I, Al Suwaidi J, Ghadban W, Salam AM. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety. Expert Opin. Drug. Saf. 12(1), 53-63 (2013).
5. Sauer EM, Sauer R, Kallmünzer B et al. Impaired renal function in stroke patients with atrial fibrillation. J. Stroke Cerebrovasc. Dis. doi:10.1016/j.jstrokecerebrovasdis.2013.10.020 (2013) (Epub ahead of print).
6. Kornej J, Hindricks G, Kosiuk J et al. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Circ. Arrhythm. Electrophysiol. 6(5), 868-874 (2013).
7. Guo Y, Wang H, Zhao X et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int. J. Cardiol. 168(5), 4678-4684 (2013).
8. Barrios V, Escobar C. Renal insufficiency should be included in stroke risk scores. Kidney Int. 83(6), 1204-1205 (2013).
9. Ahmad Y, Lip GY. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation. Contrib. Nephrol. 179, 81-91 (2013).
10. Barrios V, Calderón A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev. Esp. Cardiol. 65(1), 47-53 (2012).
11. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31(19), 2369-2429 (2010).
12. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2), 263-272 (2010).
13. Barrios V, Escobar C, Echarri R. Atrial fibrillation and coronary heart disease: fatal attraction. J. Atr. Fibrillation 1, 262-269 (2009).
14. Barra S, Providência R, Faustino C, Paiva L, Fernandes A, Leitão Marques A. Performance of the Cockcroft-Gault, MDRD and CKD-EPI formulae in non-valvular atrial fibrillation: which one should be used for risk stratification J. Atr. Fibrillation 6(3), 36-45 (2013).
15. Providência R, Fernandes A, Paiva L et al. Decreased glomerular filtration rate and markers of left atrial stasis in patients with nonvalvular atrial fibrillation. Cardiology 124(1), 3-10 (2013).
16. Piccini JP, Stevens SR, Chang Y et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127(2), 224-232 (2013).
17. Apostolakis S, Guo Y, Lane DA, Buller H, Lip GY. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur. Heart J. 34(46), 3572-3579 (2013).
18. Roldán V, Marín F, Manzano-Fernandez S et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation Thromb. Haemost. 109(5), 956-960 (2013).
19. Genovesi S, Santoro A. Anticoagulants, renal failure and atrial fibrillation. Expert Opin. Drug Saf. 12(1), 1-3 (2013).
20. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am. J. Med. 123(7), 638-645 (2010).
21. Barrios V, Escobar C. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev. Cardiovasc. Ther. 11(2), 129-141 (2013).
22. Barrios V, Escobar C. New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. Expert Opin. Pharmacother. 13(18), 2649-2661 (2012).
23. Barrios V, Escobar C, Calderon A, Roldan C. Anticoagulation in non-valvular atrial fibrillation: underused or wrongly used Am. J. Cardiol. 108(11), 1687-1688 (2011).